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Autism spectrum disorder (ASD) is a behaviorally defined disorder affecting 1 in 68 
children. Currently, there is no known cause for the majority of ASD cases nor are there 
physiological diagnostic tools or biomarkers to aid behavioral diagnosis. Whole-genome 
linkage studies, genome-wide association studies, copy number variation screening, 
and SNP analyses have identified several ASD candidate genes, but which vary greatly 
among individuals and family clusters, suggesting that a variety of genetic mutations 
may result in a common pathology or alter a common mechanistic pathway. The Akt/
mammalian target of rapamycin (mTOR) pathway is involved in many cellular processes 
including synaptic plasticity and immune function that can alter neurodevelopment. In 
this study, we examined the activity of the Akt/mTOR pathway in cells isolated from chil-
dren with ASD and typically developing controls. We observed higher activity of mTOR, 
extracellular receptor kinase, and p70S6 kinase and lower activity of glycogen synthase 
kinase 3 (GSK3)α and tuberin (TSC2) in cells from children with ASD. These data sug-
gest a phosphorylation pattern indicative of higher activity in the Akt/mTOR pathway in 
children with general/idiopathic ASD and may suggest a common pathological pathway 
of interest for ASD.
Keywords: autism, signaling, phosphorylation, T cells, mTOr
inTrODUcTiOn
Autism spectrum disorder (ASD) is characterized by severe and pervasive impairment in reciprocal 
social interaction skills, communication skills, or the presence of stereotyped behavior, interests, 
and activities (1). According to the most recent studies by the US Centers for Disease Control and 
Prevention, ASD is estimated to affect 1 in 68 children younger than 8 years (2). ASD remains a 
behaviorally defined disorder with no current physiological diagnostic tools or biological signatures. 
The cause(s) for the majority of cases of ASD remain unknown. In genetically identical monozygotic 
twins, there is a concordance rate of 44–91%; in dizygotic twins, the concordance rate for ASD is 
0–37%; and in non-twin siblings, the rate is 0–24%; data that suggest a strong heritable component 
for this disorder (3–9). Although there is evidence to suggest that the disorder is highly heritable, 
no single genetic cause for all ASD has been identified. Heritability of ASD may suggest a genetic 
component in the disorder’s etiology; however, the genes involved vary greatly among individuals 
and family clusters and therefore suggest a more likely model that a variety of genetic mutations 
and/or environmental contributors may result in a common pathology or disruption of a common 
pathway.
Table 1 | study population demographics.
group autism spectrum 
disorder (asD) 
(N = 41)
controls  
(N = 32)
Age (years), median (range) 5.7 (4.6–9.3) 5.5 (4.5–9.9)
gender
Male 32 (72%) 22 (55%)
Female 9 (28%) 10 (45%)
race/ethnicity
Caucasian, non-Hispanic 26 (64%) 24 (75%)
African American, non-Hispanic 1 (2%) –
Hispanic 8 (20%) 5 (16%)
Asian, non-hispanic 1 (2%) –
Other, non-hispanic 5 (12%) 3 (9%)
Mullen, median [interquartile 
range (iQr)]
Differential quotient (DQ) 56.1 (35.4–77.1) 105.8 (98.6–114.4)
Verbal differential quotient (VDQ) 69.1 (60.1–83.6) 105.8 (98.3–116)
Non-verbal differential quotient 
(NVDQ)
66.2 (48.4–78.9) 105.5 (99.2–112.1)
autism Diagnostic Observation 
schedule (aDOs), median (iQr)
Social affect 12 (9–16) N/A
Restricted and repetitive behavior 5 (3–6) N/A
Severity 7 (6–9) N/A
Controls with a sibling or first-degree relative with ASD were excluded from the study. 
Behavioral data include Mullen’s Scales of Early Learning (DQ, VDQ, NVDQ) scores 
with median and interquartile range and ADOS (social affect, restricted and repetitive 
behavior, severity) scores with median and interquartile range.
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Whole-genome linkage studies, genome-wide association 
studies, copy number variation screening, and SNP analyses 
have identified several ASD candidate genes (10). Associations 
between candidate genetic mechanisms and ASD have impli-
cated a diverse range of functions including metabolism, 
immune function, neuronal migration, synapse formation, 
neuronal growth, and neurotransmission. Among some of the 
notable associations are mutations in RELN (11), SHANK3 (12), 
NLGN3, NLGN4X (13), MET (14), GABRB3 (15), OXTR (16), 
and SLC6A4 (16). Furthermore, several single-gene mutation 
syndromic disorders incur increased risk of developing ASD 
including Rett syndrome (MeCP2), Fragile X (FMR1), Tuberous 
sclerosis (either TSC1 or TSC2), Cowden syndrome (PTEN), 
Timothy syndrome (CACNA1C), and Angelman syndrome 
(UBE3A) (17–19). Even with the recent advancements in iden-
tifying candidate genes involved in ASD, all identified genetic 
risk factors combined account for only 10–20% of the total 
ASD population (10). The genetic mechanisms or mutations 
are clearly diverse and heterogeneous and may be influenced by 
environmental factors.
Among the potential candidate genes identified in ASD to 
date, those involved in Akt/mammalian target of rapamycin 
(mTOR) signaling and the downstream effects of this pathway are 
highly represented including FMR1, PTEN, TSC1, and TSC2 (20). 
In addition, microarray analysis of peripheral blood suggests that 
there is abnormal activity in this pathway (21). The Akt/mTOR 
pathway is involved in many cellular processes that may impact 
neurodevelopment and have relevance to ASD symptoms. For 
example, in neurons, this pathway is believed to be important in 
the process of learning and memory formation by augmenting 
long-term potentiation (LTP) of synapses (22). The process of 
LTP involves the strengthening of synapses as a result of sustained 
signaling in the Akt/mTOR pathway (23).
The Akt/mTOR pathway is complex, and a defect in any of the 
proteins involved can lead to aberrant signaling. Increased Akt/
mTOR activity is consistent with deficiencies of FMR1, TSC1/2, 
or PTEN found in Fragile X, TSC, and Cowden syndrome and 
suggests that increased Akt/mTOR activity may have a role in the 
pathophysiology of the general ASD population and not limited 
to single ASD genetic mutations. We hypothesized that there 
are a diverse collection of physiological abnormalities including 
genetic mutation or environment factors that converge to dys-
regulate the Akt/mTOR pathway in individuals with ASD.
To probe directly for dysregulation in the Akt/mTOR pathway, 
we examined the phosphorylation activity of several proteins in 
the Akt/mTOR pathway in children with ASD and typically devel-
oping (TD) controls. Protein phosphorylation was examined in 
freshly isolated T cells (24) and following stimulation from both 
ASD and TD control children of the same age. Phosphorylation 
levels of insulin receptor substrate-1 (IRS1), phosphatase and 
tensin homolog (PTEN), tuberin (TSC2), Akt, glycogen synthase 
kinase 3 (GSK3)α, GSK3β, mTOR, p70S6 kinase (p70S6K), 
ribosomal protein S6 (RPS6), and extracellular receptor kinase 
(ERK) were measured in T cells collected from peripheral blood 
of all subjects to cast a wide net over the entirety of the Akt/mTOR 
pathway. In this study, we describe a dysregulation of Akt/mTOR 
signaling in T cells isolated from children with ASD compared 
with TD control children, data that might help point to possible 
etiological mechanisms in ASD.
MaTerials anD MeThODs
subjects and behavioral assessments
Study participants were recruited as part of the Autism Phenome 
Project (25, 26). The study protocol was approved and carried 
out in accordance with the recommendations of the Institutional 
Review Board for the UC Davis School of Medicine, and 
parents of each subject provided written informed consent for 
their child to participate in accordance with the Declaration 
of Helsinki. Participants consisted of 41 children with ASD 
[mean age (SD) = 6.13 (1.23) years, 32 males] and 31 TD con-
trols [mean age (SD) =  5.95 (1.27)  years, 22 males] (Table  1). 
Age and male:female ratios were not statistically different. 
Diagnostic instruments for ASD included the Autism Diagnostic 
Observation Schedule-Generic (ADOS-G) (27) and the Autism 
Diagnostic Interview—Revised (28). ADOS scores [mean (SD)] 
were 12.6 (3.8) for social affect, 4.6 (1.7) for restricted/repetitive 
behaviors, and 7.4 (1.9) for severity. All diagnostic assessments 
were conducted or directly observed by trained, licensed clinical 
psychologists who specialize in autism and had been trained 
according to research standards for these tools. Inclusion criteria 
for ASD were taken from the diagnostic definition of ASD in 
young children formulated and agreed upon by the Collaborative 
Programs of Excellence in Autism. Inclusion criteria for TD 
controls included developmental scores within two SDs of the 
mean on all subscales of the Mullen’s scale of early learning. 
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For ASD differential quotient (DQ) [mean (SD)] = 59.8 (27.5), 
verbal differential quotient (VDQ) = 72.3 (18.5), and non-verbal 
differential quotient (NVDQ) = 66.2 (21.7); for TD, DQ = 105.8 
(11.4), VDQ = 105.8 (12.7), and NVDQ = 105.5 (10.1). Exclusion 
criteria for TD controls included any known developmental, 
neurological, or behavioral problems; a diagnosis of mental retar-
dation, pervasive developmental disorder, or specific language 
impairment. TD children were screened and excluded for autism 
with the Social Communication Questionnaire (29) (scores > 11) 
(SCQ—Lifetime Edition). All participants were native English 
speakers, were ambulatory, and had no suspected vision or hear-
ing problems. The exclusion criteria for all subjects consisted 
of the presence of Fragile X or other serious neurological (e.g., 
seizures), psychiatric (e.g., bipolar disorder), the presence of any 
known genetic polymorphism that causes ASD, or known medi-
cal conditions including autoimmune disease and inflammatory 
bowel diseases/celiac disease. All subjects were screened via 
parental interview for current and past physical illness. Children 
with known endocrine, cardiovascular, pulmonary, liver, or 
kidney disease were excluded from enrollment in the study. No 
participant presented with a cold, fever, or other common illness, 
if such a condition occurred, the blood draw were delayed until 
the child’s health status was stable for 48 h.
Peripheral blood Mononuclear cell 
(PbMc) collection
Peripheral blood was collected in acid-citrate-dextrose 
Vacutainers (BD Biosciences, San Jose, CA, USA) following 
behavioral assessments. Whole blood was centrifuged at 960 g for 
10 min to separate cell fractions from plasma. The cell fraction 
was diluted in 25  ml of Hank’s Balanced Salt Solution (HBSS) 
(Mediatech, Manassas, VA, USA) and layered at room tempera-
ture over lymphocyte separation medium (LSM) (Mediatech) and 
centrifuged at 300 g for 30 min to isolate PBMCs. PBMCs were 
harvested at the interface between LSM and HBSS fractions and 
washed twice with 50 ml HBSS. The number of viable PBMC was 
determined by 1:1 dilution of Trypan Blue (Mediatech) exclusion 
counting on a Hausser phase contrast hemacytometer. Cells were 
then diluted in a chilled (4°C) magnetic separation buffer (MACS 
buffer) (Miltenyi Biotec, Auburn, CA, USA) to a concentration of 
2.5 × 108/ml.
T cell isolation
T cells were isolated with a Pan T cell isolation kit according to the 
protocol provided by the manufacturer (Miltenyi Biotec). Briefly, 
a biotinylated antibody cocktail containing antibodies reactive 
to CD14, CD15, CD16, CD19, CD34, CD36, CD56, CD123, and 
CD235a (glycophorin A) was added at a concentration of 10 μl 
of antibody cocktail/107 cells and incubated for 10 min at 4°C. 
Following incubation, an additional 30 μl of MACS buffer per 107 
cells was added followed by 10 μl of magnetic beads conjugated 
to antibiotin antibodies at a concentration of 20 μl/107 cells and 
incubated at 4°C for an additional 15 min. Cells were then washed 
in 20-fold incubation volume of MACS buffer and centrifuged 
at 300 g for 10 min. Supernatants were aspirated and discarded, 
and PBMC were resuspended in 500  μl. This suspension was 
transferred to a MACS LS column on a MACS magnetic platform. 
The column was washed with a total of 9 ml MACS buffer, and 
eluent was again collected. All of the T cell-enriched eluent that 
passed through the LS column from the column was collected 
and centrifuged at 300 g for 10 min. The T cell-enriched pellet was 
washed and centrifuged twice in 10 ml of Roswell Park Memorial 
Institute (RPMI) media (Life technologies) containing 10% low 
endotoxin, heat-inactivated fetal bovine serum (Life technolo-
gies, Carlsbad, CA, USA), 100 IU/ml penicillin, and 100 IU/ml 
streptomycin (Sigma, St. Louis, MO, USA) (complete RPMI). 
The T cells were then resuspended in 1 × 106 cell/ml and plated 
1  ml/well in a 12-well sterile tissue culture plate (Greiner Bio-
One, Monroe, NC, USA). T cells were allowed to rest in complete 
RPMI at 37°C for 16 h prior to stimulation and lysis.
T cell stimulation, lysis, and Protein 
Quantification
T cells were either left unstimulated or stimulated with 10 nM 
phorbol myristate acetate (PMA) for 15 or 45 min in complete 
RPMI at 37°C. Following stimulation, T cells were quickly washed 
in 10 ml of ice-cold PBS and centrifuged for 10 min at 500 g at 
4°C. Supernatants were aspirated, and cell pellet was resuspended 
in ice-cold lysis buffer (Cell Signaling Technology, Danvers, MA, 
USA) containing 20  mM Tris-HCl (pH 7.5), 150  mM NaCl, 
1  mM Na2EDTA, 1  mM EGTA, 1% Triton X, 2.5  mM sodium 
pyrophosphate, 1  mM beta-glycerophosphate, 1  mM Na3VO4, 
and 1  μg/ml leupeptin supplemented with freshly added 1% 
AEBSF. Cells were mixed in lysis buffer with vigorous pipetting 
and sonicated for 30 s. Cells were then incubated in lysis buffer on 
ice for 10 min. Following incubation, cell suspensions were cen-
trifuged at 18,000 g for 10 min. Supernatants were collected, and 
aliquots were stored at −80°C until date of protein quantification 
or phosphorylation analysis. Protein levels were quantified using 
Bradford assay. In brief, diluted lysate and BSA standards were 
combined 1:1 with room temperature Bradford reagent (Bio-Rad, 
Hercules, CA, USA) and incubated for 10 min. Following incuba-
tion, optical density was measured with a 595 λ filter on a Bio-Rad 
spectrophotometer. Protein levels of T cell lysate samples were 
derived from a linear seven-point BSA standard curve (Bio-Rad).
Phosphorylation assay
Relative levels of phosphorylated and total IRS1, PTEN, ERK1/2, 
Akt, GSK3α, GSK3β, TSC2, mTOR, p70S6K, and RPS6 were 
measured with Milliplex™ multiplexing bead immunoassays 
(Millipore, Billerica, MA, USA). This assay contains antibodies 
that have been standardized and optimized for sensitivity and 
specificity to detect the phosphorylation and total protein levels 
of the molecules tested. Assay detection of the total and phos-
phorylated proteins detected was confirmed using Western blot 
analysis of individual phosphorylated or total proteins prior to 
testing, as well as the manufacturer’s own internal research qual-
ity controls. A subset of samples was also put through a second 
assay provided by Bio-Rad that contains many of standardized 
antibodies used in Western blot analyses, with strong correlation 
between assays (data not shown). Luminex technology provides 
a unique platform for analysis of limited sample volume, as is the 
Table 2 | akt/mTOr pathway total protein in T cells.
 Protein asD control p Value
Median interquartile 
range (iQr)
Median iQr
activating
Unstimulated
Akt 0.175 0.132 0.169 0.088 0.708
Mammalian target of 
rapamycin (mTOR)
0.016 0.012 0.015 0.005 0.741
p70S6 kinase 
(p70S6K)
0.250 0.092 0.221 0.094 0.406
Ribosomal protein S6 
(RPS6)
0.005 0.002 0.004 0.001 0.017
Extracellular receptor 
kinase (ERK)
0.655 0.149 0.646 0.076 0.551
stimulated (15 min)
Akt 0.173 0.124 0.171 0.085 0.792
mTOR 0.014 0.008 0.016 0.007 0.377
p70S6K 0.263 0.110 0.265 0.109 0.474
RPS6 0.006 0.004 0.005 0.002 0.001
ERK 0.604 0.196 0.605 0.155 0.669
stimulated (45 min)
Akt 0.168 0.107 0.169 0.090 0.853
mTOR 0.018 0.008 0.016 0.009 0.071
p70S6K 0.270 0.089 0.273 0.141 0.966
RPS6 0.014 0.016 0.009 0.008 0.003
ERK 0.607 0.115 0.617 0.118 0.664
inactivating
Unstimulated
Insulin receptor 
substrate-1 (IRS1)
0.027 0.026 0.018 0.022 0.030
PTEN 0.289 0.156 0.255 0.079 0.129
Glycogen synthase 
kinase 3 (GSK) 3α
0.282 0.275 0.254 0.203 0.729
GSK3β 0.269 0.238 0.260 0.130 0.544
TSC2 0.040 0.049 0.039 0.056 0.590
stimulated (15 min)
IRS1 0.030 0.023 0.021 0.020 0.041
PTEN 0.307 0.146 0.266 0.075 0.067
GSK3α 0.209 0.245 0.280 0.214 0.053
GSK3β 0.153 0.169 0.168 0.143 0.378
TSC2 0.043 0.050 0.036 0.056 0.538
stimulated (45 min)
IRS1 0.040 0.028 0.024 0.031 0.004
PTEN 0.284 0.114 0.245 0.074 0.078
GSK3α 0.210 0.186 0.276 0.131 0.065
GSK3β 0.115 0.109 0.159 0.128 0.147
TSC2 0.040 0.049 0.035 0.056 0.866
All p values were calculated with two-tailed Mann–Whitney U-tests.
Values in bold and gray shades signifies a p < 0.05.
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case in this study, where precious blood samples from pediatric 
patients are used. GAPDH was used as an internal control for 
both phoshporylated and total protein assays, which were meas-
ured separately. The multiplex assay was performed according to 
the manufacturer’s instructions. Briefly, lysates were incubated 
with antibody-conjugated beads at a total protein concentration 
of 500 μg/ml. After protein capture, beads were washed twice fol-
lowed by incubation with biotinylated detection antibody. Beads 
were then incubated with streptavidin-conjugated phycoerythrin 
(PE), followed by several washes. Finally, the bead sets were 
analyzed using a flow-based Luminex™ 100 suspension array 
system to determine bead identity and corresponding PE mean 
fluorescent intensity (MFI) (Bio-Plex 200; Bio-Rad Laboratories). 
Relative levels of phosphorylated and total proteins were deter-
mined by dividing MFI signal of each protein by GAPDH signal 
for each sample. Relative phosphorylation was determined by 
further dividing the GAPDH relative levels of phosphorylated 
proteins to their respective GAPDH relative total protein levels. 
All phosphorylation values are expressed as ratios.
statistical analysis
The data were non-parametrically distributed, p values were deter-
mined with Mann–Whitney U-test. All analyses were two tailed, 
and values of p < 0.05 were considered statistically significant. 
For these novel and previously untested experiments, unadjusted 
p values are presented (30). All analyses were conducted using 
GraphPad Prism statistical software (GraphPad Software Inc., 
San Diego, CA, USA). Associations between Akt/mTOR/pathway 
measures and behaviors assessed by ADOS were calculated using 
a two-tailed, non-parametric Spearman’s correlation test with 
95% confidence intervals.
resUlTs
Given that Akt/mTOR genetic mutations are potentially associ-
ated with increased ASD risk, we hypothesized that aberrations in 
many parts of the Akt/mTOR pathway will contribute to an overall 
pattern of increased Akt/mTOR pathway activity. To test this the-
ory, we examined several proteins in the Akt/mTOR pathway. We 
observed increased IRS1 and RSP6 total protein in children with 
ASD compared with TD controls under unstimulated conditions 
(p < 0.03; Table 2). Similarly, total IRS1 and RSP6 were increased, 
in T cells following 15 or 45 min of stimulation, in the ASD group 
compared to TD controls (p < 0.04). No other total protein levels 
were different between groups (Table  2). For phosphorylated 
proteins, in unstimulated T cells, GSK3α, GSK3β, PTEN, TSC2, 
and mTOR were increased in children with ASD compared to TD 
controls (p < 0.006; Table 3). After 15 min of stimulation, T cells 
from children with ASD had higher phosphorylation of proteins, 
p7056K, IRS1, GSK3α, GSK3β, AKT, PTEN, TSC2, mTOR, and 
ERK (p < 0.04; Table 3). After 45 min of T cell stimulation, levels 
of phosphorylated protein were still increased in children with 
ASD for p7056K, IRS1, GSK3α, GSK3β, AKT, PTEN, TSC2, 
mTOR, and ERK, as well as RPS6 (p < 0.02; Table 3).
By calculating the ratio of phosphorylated to total protein 
levels, we observed higher ratios for mTOR and GSK3β (p < 0.02) 
in unstimulated ASD T cells when compared to unstimulated TD 
control T cells (Table 4; and Figures S1 and S2 in Supplementary 
Material). Given the effects of phosphorylation on these proteins 
(Table  5), it would indicate increased activity of mTOR and 
decreased activity of GSK3β in ASD T cells. This may suggest 
Table 3 | akt/mTOr pathway phosphorylated protein in T cells.
Protein asD control p Value
Median interquartile 
range (iQr)
Median iQr
activating
Unstimulated
Akt 0.006 0.004 0.005 0.003 0.110
Mammalian target of 
rapamycin (mTOR)
0.024 0.017 0.015 0.012 0.006
p70S6 kinase 
(p70S6K)
0.011 0.007 0.008 0.004 0.064
Ribosomal protein S6 
(RPS6)
0.009 0.006 0.009 0.005 0.473
Extracellular receptor 
kinase (ERK)
0.006 0.004 0.006 0.002 0.211
stimulated (15 min)
Akt 0.008 0.005 0.005 0.006 0.013
mTOR 0.099 0.088 0.057 0.088 0.011
p70S6K 0.093 0.142 0.027 0.125 0.018
RPS6 0.060 0.071 0.013 0.070 0.085
ERK 0.153 0.150 0.080 0.195 0.029
stimulated (45 min)
Akt 0.008 0.005 0.005 0.005 0.006
mTOR 0.127 0.094 0.071 0.107 0.002
p70S6K 0.142 0.140 0.069 0.145 0.003
RPS6 0.137 0.221 0.035 0.200 0.023
ERK 0.104 0.094 0.043 0.103 0.005
inactivating
Unstimulated
Insulin receptor 
substrate-1 (IRS1)
0.005 0.004 0.004 0.003 0.064
PTEN 0.219 0.097 0.170 0.074 0.000
Glycogen synthase 
kinase 3 (GSK3)α
0.015 0.012 0.011 0.005 0.002
GSK3β 0.023 0.021 0.012 0.014 0.000
TSC2 0.016 0.012 0.013 0.006 0.001
stimulated (15 min)
IRS1 0.009 0.007 0.004 0.008 0.009
PTEN 0.208 0.119 0.175 0.111 0.045
GSK3α 0.317 0.326 0.161 0.361 0.009
GSK3β 0.116 0.099 0.064 0.118 0.023
TSC2 0.052 0.039 0.034 0.054 0.027
stimulated (45 min)
IRS1 0.010 0.016 0.005 0.006 0.003
PTEN 0.233 0.176 0.164 0.050 0.001
GSK3α 0.307 0.303 0.107 0.263 0.001
GSK3β 0.113 0.077 0.067 0.089 0.002
TSC2 0.054 0.046 0.028 0.039 0.000
Median and IQR of phosphorylated Akt/mTOR pathway proteins. All p values were 
calculated with two-tailed Mann-Whitney U-tests.
Values in bold and gray shades signifies a p < 0.05.
Table 4 | akt/mTOr pathway phosphorylated/total protein ratios in  
T cells.
Protein asD control p Value
Median interquartile 
range (iQr)
Median iQr
activating
Unstimulated
Akt 0.039 0.050 0.028 0.021 0.544
Mammalian target of 
rapamycin (mTOR)
1.262 1.529 0.941 0.866 0.024
p70S6 kinase 
(p70S6K)
0.041 0.038 0.035 0.019 0.254
Ribosomal protein S6 
(RPS6)
1.685 1.532 1.995 1.395 0.590
Extracellular receptor 
kinase (ERK)
0.009 0.009 0.009 0.004 0.597
stimulated (15 min)
Akt 0.053 0.046 0.039 0.038 0.129
mTOR 5.954 6.491 2.770 5.730 0.016
p70S6K 0.342 0.653 0.104 0.357 0.002
RPS6 5.787 7.306 3.298 10.334 0.274
ERK 0.227 0.288 0.127 0.367 0.027
stimulated (45 min)
Akt 0.062 0.058 0.036 0.042 0.078
mTOR 6.769 6.872 3.929 5.815 0.008
p70S6K 0.503 0.588 0.225 0.417 0.004
RPS6 9.008 8.853 4.325 17.095 0.087
ERK 0.178 0.168 0.078 0.186 0.050
inactivating
Unstimulated 
Insulin receptor 
substrate-1 (IRS1)
0.235 0.294 0.250 0.224 0.346
PTEN 0.681 0.461 0.647 0.278 0.115
Glycogen synthase 
kinase 3 (GSK3)α
0.072 0.283 0.043 0.090 0.057
GSK3β 0.073 0.111 0.050 0.042 0.010
TSC2 0.428 2.717 0.360 1.653 0.153
stimulated (15 min)
IRS1 0.305 0.695 0.275 0.347 0.834
PTEN 0.680 0.452 0.673 0.276 0.636
GSK3α 1.409 6.295 0.505 1.964 0.004
GSK3β 0.808 0.921 0.484 0.969 0.055
TSC2  1.797 7.840 0.867 2.747 0.039
stimulated (45 min)
IRS1 0.232 0.374 0.254 0.352 0.874
PTEN 0.860 0.445 0.663 0.207 0.025
GSK3α 1.199 4.969 0.364 1.290 0.004
GSK3β 0.977 0.783 0.523 0.899 0.017
TSC2 1.548 5.008 0.786 1.909 0.029
Median and IQR of phosphorylated/total Akt/mTOR pathway proteins. All p values were 
calculated with two-tailed Mann–Whitney U-tests.
Values in bold and gray shades signifies a p < 0.05.
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higher activity of Akt/mTOR signaling in ASD T cells (Figure 1). 
ASD T cells also trended toward increased phosphorylation of 
GSK3α under unstimulated conditions (Table 5), which would 
indicate lower activity of GSK3α consistent with higher Akt/
mTOR pathway activity (Table 1). Together these data indicate 
Akt/mTOR signaling is higher in resting T cells of children with 
ASD when compared with T cells from TD controls.
After stimulation with PMA for 15 min, T cells from children 
with ASD exhibited higher phosphorylation of ERK, mTOR, 
FigUre 1 | akt/mTOr signaling schematic. The PI3K pathway in 
response to stimulation with phorbol myristate acetate (PMA). Autism 
spectrum disorder-associated mutations are shown in orange, while all others 
are shown in blue. Molecules measured in this study are shown with white 
lettering.
Table 5 | effect of phosphorylation on target sites of akt/mTOr pathway 
proteins.
                          activating inactivating
Akt Ser473 IRS1 Ser312
mTOR Ser2448 PTEN Ser380
p70S6K Thr412 GSK3α Ser21
RPS6 Ser235/Ser236 GSK3β Ser9
ERK Thr185/Tyr187 TSC2 Ser939
Proteins are organized according to whether the effect of phosphorylation on a specific 
phosphorylation site is activating or inactivating. The sites listed in the table are those 
measured in this article.
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p70S6K, GSK3α, and TSC2 compared with T cells from children 
with TD (p < 0.04; Table 4), indicating increased activity of ERK, 
mTOR, and p70S6K but a decreased activity of inhibitory signals 
by TSC2 and GSK3α, suggesting that Akt/mTOR pathway activity 
may be increased in stimulated ASD T cells (Table  1). ASD T 
cells also trended toward increased phosphorylation of GSK3β 
(p <  0.054), which would indicate lower activity of inhibitory 
GSK3β consistent with higher Akt/mTOR pathway activity. After 
45 min of PMA stimulation, increased phosphorylation of ERK, 
mTOR, p70S6K, GSK3α, GSK3β, PTEN, and TSC2 were detected 
in ASD T cells (Table 4). There was also a trend for increased AKT 
but which did not quite reach statistical significance (p = 0.077). 
Together these data suggest overall increased AKT/mTOR path-
way activity in ASD T cells following stimulation.
Associations were observed for total p7056k and autism sever-
ity at 15 min poststimulation (r = 0.327, p = 0.04). Restrictive 
and repetitive behaviors were associated with the PTEN ratio 
after 15 min stimulation also (r = −0.3316, p = 0.03). For social 
affect, several measures were associated including total p7056k 
and the IRIS ratio in unstimulated and 45 min after stimulation 
(p < 0.05).
DiscUssiOn
In this study, we report differential activity of several Akt/mTOR 
signaling molecules in young children with ASD. To observe 
dynamic phosphorylation activity, freshly isolated T lympho-
cyte cells were chosen as a cellular representative that could be 
acquired efficiently, safely, and easily from relatively non-invasive 
blood samples. From our experiments, we determined that ASD 
T cells generally exhibit phosphorylation to total protein ratios 
that would indicate higher activity of mTOR, ERK, and p70S6K 
as well as lower activity of GSK3α, GSK3β, TSC2, and PTEN 
than TD control T cells. This indicates a shift toward higher Akt/
mTOR pathway activity in the ASD group (Table 5; Figure 1). 
An increased Akt/mTOR activity is consistent with deficiencies of 
FMR1, TSC1/2, or PTEN found in Fragile X, TSC, and Cowden 
syndrome, respectively (31–33). Moreover, suppression of this 
increased Akt/mTOR activity has been demonstrated to improve 
ASD-associated symptoms in mice deficient for PTEN and TSC1 
(34, 35). Together these data suggest that increased Akt/mTOR 
activity may have a role in the pathophysiology of the general 
ASD population and not limited to known ASD-associated Akt/
mTOR genetic mutations.
The Akt/mTOR pathway is involved in a large number of 
physiological functions, in both the central nervous and immune 
systems (36–39). Atypical Akt/mTOR signaling may be related to 
many previous observations of abnormal T cell function (40–44) 
in children with ASD. The aberrancies in Akt/mTOR signaling 
observed in this study are likely not limited to T cells but will 
have relevance to signaling also in other immune cells and as 
such these data have relevance to other immune abnormalities 
previously observed in ASD involving multiple leukocyte subsets 
(25, 45–50). Aberrant Akt/mTOR signaling has the potential to 
impact cellular growth, proliferation, and cytokine production in 
the immune system (38), which can in turn affect behavior (26).
Our data show that immune dysfunction of children with ASD 
previously demonstrated may stem from aberrant T cells signaling 
via the Akt/mTOR pathway. To probe directly for dysregulation 
in the Akt/mTOR pathway, we sought to examine the phospho-
rylation activity of several proteins in the Akt/mTOR pathway in 
children with ASD and TD controls. As ASD manifests in early 
childhood, it is difficult to find suitable research tools and accessi-
ble tissues for experimentation. For example, postmortem human 
tissue can never provide the substrate for dynamic functional 
studies, and finding suitable control material is problematic. 
Immune cells, in contrast, provide a readily accessible model 
system that has many advantages including easy acquisition, high 
availability, and fine matching with controls. The advantages of 
using lymphocytes as an easily accessible “neural probe” in the 
investigation of psychiatric disorders in living subjects has been 
previously reviewed (24). We therefore utilized T lymphocytes 
as a neuronal surrogate in our experiments to examine dynamic 
signaling activity. T lymphocyte cells were chosen as a cellular 
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model in which to test Akt/mTOR pathway activity for several 
characteristics including their long life span and high numbers 
within the blood. Moreover, the Luminex technology was chosen 
as it provides a platform for analyses of a number of analytes 
simultaneously from small volumes of tissue. As this study uti-
lized pediatric blood samples, T cell numbers were limited, and 
thus, performing Western blot analyses on all phosphorylated 
or total proteins would be prohibitive. Importantly, the antibod-
ies used had been previously standardized and optimized, and 
we also checked for detection of the same proteins in Western 
blot analysis and intracellular flow cytometry techniques, using 
Jurkat cells and primary T cells from adults, prior to running the 
Luminex assays. In addition, on a subset of samples, a number 
of phosphorylated or total proteins were compared between 
two Luminex assays from different manufacturer’s, with similar 
results. Our results suggest that the Luminex platform provides a 
quick and efficient means of identifying possible changes in the 
Akt/mTOR pathway, in pediatric samples that are limited in vol-
ume. Although our data showed increased Akt/mTOR signaling 
in ASD, whether this reflects what happens in vivo or within other 
tissues such as the gastrointestinal tract or brain is not known and 
would need further investigation.
Further work needs to be performed to determine context-
dependent effects on Akt/mTOR pathway in T cells and how 
they relate to the brain; however, many gene expression studies 
have taken the approach to look at primary or immortalized 
blood cells as a surrogate for inaccessible tissue such as the brain. 
The advantages of using lymphocytes as neural surrogates for 
in vitro examination has been previously established, but there 
is also evidence that the increased Akt/mTOR activity observed 
in Fragile X central nervous system (CNS) tissue is mirrored in 
lymphocytes (51), suggesting that Akt/mTOR signaling in T cells 
is applicable to cells of the CNS, including neurons and glial cells. 
In neurons, the Akt/mTOR pathway is essential in the regulation 
of dendritic arborization and spine formation (52), which are 
important features of synapse formation. Increased activity of this 
pathway in neuronal knockouts of TSC1 or PTEN results in lower 
sociability and seizures in mouse models (53–55), suggesting that 
both sociability and seizures are Akt/mTOR pathway activity 
dependent. Increased activity of this pathway in glial cells can also 
have negative effects on neurobiology, such as aberrant neuronal 
organization and seizures in astrocyte-specific TSC1 conditional 
knockout mice (56). Lack of social interactions is a central 
symptom of ASD (1), and seizures are a common comorbidity 
in the disorder (57). Together these data suggest that these ASD 
symptoms could be potentially related to the high Akt/mTOR 
signaling as described in this study in ASD cells (53, 56, 58).
Akt activation leads to a number of effects, some of which are 
mTOR independent. These include regulating cell survival and 
growth, such as phosphorylation of Forkhead box O family of 
transcription factors and of GSK3α and GSK3β (59–61). GSK3 
exists in two genetically distinct isoforms but with near identi-
cal function. GSK3α and GSK3β share 85% amino acid identity 
and 98% amino acid sequence homology within their kinase 
domains (62). The GSK3 proteins are involved in regulating 
metabolic function and are phosphorylated and inhibited by Akt 
among other kinases such as p70S6K. Once phosphorylated, the 
kinase activity of GSK3 is inhibited, and their substrates such as 
glycogen synthase, Ap-1, β-catenin, c-myc, and p53, thereby initi-
ating signaling mechanisms promoting cell survival and growth. 
GSK3s are expressed in virtually all cell types, but their expression 
is highly enriched in the CNS (63) and appears to be involved in 
regulating synaptic plasticity (64). These proteins have recently 
gained attention in the area of Alzheimer’s disease (AD) research, 
and there have been several observations that both the activity 
and total levels of GSK3 is upregulated in AD patients (65). 
Interestingly, we observed lower GSK3 activity in children with 
ASD compared with TD controls. Current evidence suggests that 
low GSK3 activity impairs LTD (66), which could affect synaptic 
plasticity and in children with ASD.
Collectively, these data described in this study suggest a 
general dysregulation of the Akt/mTOR pathway in an idiopathic 
ASD population. This may suggest a convergent pathology in 
ASD that would affect multiple physiological symptoms. It is 
unclear whether Akt/mTOR aberrancies described in the study 
are due to as yet unknown genetic mutations, epigenetic changes, 
or environmental factors, and it is possible that it may be due to 
a combination of genetic and environmental influences. In fact, 
growth factors that imbue effects by signaling through the Akt/
mTOR pathway such as HGF and MIF have also been reported 
as dysregulated in ASD (67, 68), suggesting that circulatory 
homeostatic factors can be an additional source of Akt/mTOR 
pathway activity. Similarly, a mutation in cMET, the receptor for 
HGF, has also been reported in ASD (69), suggesting that Akt/
mTOR-associated receptors may also be a source for aberrant 
signaling activity. Together, these data present a novel finding 
Akt/mTOR pathway dysregulation in young children with ASD 
that could provide a focus for targeted therapeutics for at least a 
subset of individuals with ASD.
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